15-Hydroxy Lubiprostone D9
| Product Name | 15-Hydroxy Lubiprostone D9 |
|---|---|
| Alternate Names | Lubiprostone Stable Isotopes, Stable Isotopes of Lubiprostone |
| CAT No. | CS-BU-00120 |
| CAS No. | 475992-30-4 |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | 401.53 g/mol |
| Mol. For. | C20H25D9F2O5 |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Lubiprostone |
| Smileys | OC(CC[C@H]([C@H]1CCCCCCC(O)=O)[C@H](O)CC1=O)C(F)(C([2H])([2H])C([2H])(C([2H])(C([2H])([2H])[2H])[2H])[2H])F |
| Canonical Smiles | CCCCC(C(CCC1C(CC(=O)C1CCCCCCC(=O)O)O)O)(F)F |
| InchIKey | PNVYHTHOCKTJCO-MWPGWRTMSA-N |
| Inchl | InChI=1S/C20H34F2O5/c1-2-3-12-20(21,22)18(25)11-10-15-14(16(23)13-17(15)24)8-6-4-5-7-9-19(26)27/h14-15,17-18,24-25H,2-13H2,1H3,(H,26,27)/t14-,15-,17-,18?/m1/s1 |
| IUPAC | 7-[(1R,2R,3R)-2-(4,4-difluoro-3-hydroxyoctyl)-3-hydroxy-5-oxocyclopentyl]heptanoic acid |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
15-Hydroxy Lubiprostone D9 is a deuterated derivative of Lubiprostone, a medication used for the treatment of chronic idiopathic constipation and irritable bowel syndrome. This advanced compound is synthesized by introducing deuterium atoms into the molecular structure of Lubiprostone, which enhances its stability, potency, and efficacy.
Chemically, 15-Hydroxy Lubiprostone D9 is a prostone, an endogenous fatty acid that activates chloride channels in the gastrointestinal tract, thereby increasing fluid secretion and improving intestinal motility. It works by binding to and activating CIC-2 channels on the apical membrane of intestinal epithelial cells, which leads to the influx of chloride ions and the subsequent efflux of bicarbonate and water. This mechanism of action promotes the formation of softer stools, reduces the frequency of bowel movements, and relieves symptoms such as bloating, abdominal pain, and discomfort.
15-Hydroxy Lubiprostone D9 is administered orally in the form of capsules, and it undergoes rapid absorption and metabolism in the liver. Its bioavailability is estimated to be around 60%, and its half-life is approximately 3 hours. The drug is largely excreted in the feces, with minimal renal elimination.
In conclusion, 15-Hydroxy Lubiprostone D9 is a promising medication for the treatment of gastrointestinal disorders, offering improved pharmacokinetics and pharmacodynamics compared to its parent compound. Its selective activation of chloride channels in the intestine provides a safe and effective approach to managing chronic constipation and irritable bowel syndrome.
Get an Instant Quote
Related Compounds
O-Tetrahydropyranyl Lubiprostone-d7 | Lubiprostone D9 | Lubiprostone D7 |